Natasha K Brockwell

TL;DR: Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling mediates almost all immune regulatory processes, including those that are involved in tumor cell recognition and tumor-driven immune escape.

TL;DR: It is demonstrated that loss of tumor‐intrinsic type I IFN occurs in proliferating prostate cancer cells in bone, which suppresses tumor immunogenicity and therapeutic response and promotes bone cell activation to drive cancer progression.

TL;DR: Myoepithelial cell stefin A is identified as a suppressor of early tumor invasion and a candidate marker to distinguish patients who are at low risk of developing invasive breast cancer, and can therefore be spared further treatment.

TL;DR: It is critical to investigate the impact of intratumoral agents on subsequent metastatic spread to predict clinical impact, and Repeated systemic dosing with recombinant IFNs or IFN inducers is associated with significant toxicities; hence, the use of alternate intrumoral agents is an active area of investigation.

TL;DR: It is demonstrated that measurement of T-cell subsets and effector function throughout chemotherapy predicts risk of metastatic relapse and the tumor inherent interferon regulatory factor IRF9 expression may offer early insight into TNBC patient prognosis and tumor heat, allowing for identification of patients that are unlikely to respond to chemotherapy alone and could benefit from further immune-based therapeutic intervention.